{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:24:52Z","timestamp":1793521492008,"version":"4.5.0"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Metabolic dysfunction\u2013associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease and is projected to become the leading indication for liver transplant (LT) in the US. Understanding its clinical burden can help to identify opportunities for prevention and treatment.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To project the burden of MASLD in US adults from 2020 to 2050.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This decision analytical modeling study used an agent-based state transition model that simulates the natural history of MASLD progression among adults 18 years of age or older. Primary data sources for model inputs were the published literature.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Natural history of MASLD.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Cases of MASLD, metabolic dysfunction\u2013associated steatohepatitis (MASH), fibrosis, hepatocellular carcinoma (HCC), LT, and liver-related death.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The model simulated 2\u202f821\u202f624 individuals (mean age. 35.8 years; 50.9% female). The model predicted a steady increase in the prevalence of MASLD from 33.7% (86.3 million people) in 2020 to 41.4% (121.9 million people) by 2050. Cases of MASH would increase from 14.9 million (5.8% of US adults) in 2020 to 23.2 million (7.9% of US adults) by 2050. The number of cases of MASH and clinically significant fibrosis (ie, F\u2265F2, centrilobular and periportal fibrosis or more severe disease) were estimated to increase from 6.7 million to 11.7 million. By 2046 to 2050, MASLD would cause 22\u202f440 new cases of HCC and 6720 new cases of LT per year compared with 11\u202f483 new cases of HCC and 1717 new cases of LT in 2020 to 2025. Liver-related mortality was estimated to increase from 30\u202f500 deaths (1.0% of all-cause deaths in adults) in 2020 to 95\u202f300 deaths (2.4%) in 2050.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this decision analytical modeling study, the model forecast a substantial increase in clinical burden of MASLD over the next 3 decades in the absence of effective treatments. These results suggest that health systems should plan for large increases in the number of HCC cases and in the need for LT.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.54707","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:31:14Z","timestamp":1737113474000},"page":"e2454707","source":"Crossref","is-referenced-by-count":273,"title":["Estimated Burden of Metabolic Dysfunction\u2013Associated Steatotic Liver Disease in US Adults, 2020 to 2050"],"prefix":"10.1001","volume":"8","author":[{"given":"Phuc","family":"Le","sequence":"first","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moosa","family":"Tatar","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"},{"name":"University of Houston School of Pharmacy, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasan","family":"Dasarathy","sequence":"additional","affiliation":[{"name":"Department of Inflammation and Immunity, Lerner Research Institute, Cleveland, Ohio"},{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naim","family":"Alkhouri","sequence":"additional","affiliation":[{"name":"Department of Hepatology, Arizona Liver Health, Tucson"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Herman","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor"},{"name":"University of Michigan School of Medicine, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen B.","family":"Taksler","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Deshpande","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Ye","sequence":"additional","affiliation":[{"name":"University of Michigan School of Public Health, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olajide A.","family":"Adekunle","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"McCullough","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hepatology, and Nutrition, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[{"name":"Center for Value-Based Care Research, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"issue":"4","key":"zoi241536r1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"zoi241536r2","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.","volume":"7","author":"Riazi","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"zoi241536r3","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"zoi241536r4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease.","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"5","key":"zoi241536r5","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"zoi241536r6","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"zoi241536r7","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1111\/joim.13343","article-title":"Risk for hepatic and extra-hepatic outcomes in nonalcoholic fatty liver disease.","volume":"292","author":"Hagstr\u00f6m","year":"2022","journal-title":"J Intern Med"},{"key":"zoi241536r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.05.019","article-title":"NASH is the leading cause of hepatocellular carcinoma in liver transplant candidates.","author":"Koh","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi241536r9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.cgh.2018.05.057","article-title":"Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates.","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"zoi241536r10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances.","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"zoi241536r11","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000352","article-title":"The changing epidemiology of adult liver transplantation in the United States in 2013-2022: the dominance of metabolic dysfunction\u2013associated steatotic liver disease and alcohol-associated liver disease.","volume":"8","author":"Younossi","year":"2023","journal-title":"Hepatol Commun"},{"issue":"2","key":"zoi241536r12","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","article-title":"99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical.","volume":"80","author":"Hagstr\u00f6m","year":"2024","journal-title":"J Hepatol"},{"key":"zoi241536r13","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000604","article-title":"National prevalence estimates for steatotic liver disease and subclassifications using consensus nomenclature.","author":"Lee","journal-title":"Hepatology"},{"issue":"1","key":"zoi241536r14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"zoi241536r15","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","article-title":"American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD).","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"issue":"2","key":"zoi241536r16","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis.","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"3","key":"zoi241536r17","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"59","author":"Wong","year":"2013","journal-title":"J Hepatol"},{"issue":"8","key":"zoi241536r18","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/j.cgh.2023.03.041","article-title":"Clinical trial landscape in NASH.","volume":"21","author":"Harrison","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"zoi241536r19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis.","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"zoi241536r20","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis.","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"issue":"10215","key":"zoi241536r21","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"zoi241536r22","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"zoi241536r23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"zoi241536r24","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States.","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"zoi241536r25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/17477778.2018.1442155","article-title":"Strengthening the reporting of empirical simulation studies: introducing the STRESS guidelines.","volume":"13","author":"Monks","year":"2018","journal-title":"J Simul"},{"issue":"2","key":"zoi241536r26","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jval.2015.01.006","article-title":"Selecting a dynamic simulation modeling method for health care delivery research-part 2: report of the ISPOR Dynamic Simulation Modeling Emerging Good Practices Task Force.","volume":"18","author":"Marshall","year":"2015","journal-title":"Value Health"},{"issue":"5","key":"zoi241536r28","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1002\/hep.29546","article-title":"Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study.","volume":"67","author":"Allen","year":"2018","journal-title":"Hepatology"},{"key":"zoi241536r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.07.033","article-title":"Disease state transition probabilities across the spectrum of NAFLD: a systematic review and meta-analysis of paired biopsy or imaging studies.","author":"Le","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"zoi241536r30","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.24491","article-title":"The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.","volume":"54","author":"Bhala","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"zoi241536r31","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1002\/hep4.1625","article-title":"The natural history of NAFLD, a community-based study at a large health care delivery system in the United States.","volume":"5","author":"Nyberg","year":"2021","journal-title":"Hepatol Commun"},{"issue":"6","key":"zoi241536r32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/hep.30664","article-title":"The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials.","volume":"70","author":"Sanyal","year":"2019","journal-title":"Hepatology"},{"issue":"17","key":"zoi241536r33","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","article-title":"Prospective study of outcomes in adults with nonalcoholic fatty liver disease.","volume":"385","author":"Sanyal","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi241536r34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2018.04.034","article-title":"Fibrosis severity as a determinant of cause-specific mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study.","volume":"155","author":"Vilar-Gomez","year":"2018","journal-title":"Gastroenterology"},{"issue":"4","key":"zoi241536r35","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/hep.21103","article-title":"Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.","volume":"43","author":"Sanyal","year":"2006","journal-title":"Hepatology"},{"issue":"5","key":"zoi241536r39","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.jhep.2024.01.014","article-title":"Clinical profiles and mortality rates are similar for metabolic dysfunction\u2013associated steatotic liver disease and non-alcoholic fatty liver disease.","volume":"80","author":"Younossi","year":"2024","journal-title":"J Hepatol"},{"issue":"3","key":"zoi241536r41","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1136\/gutjnl-2022-327777","article-title":"Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis.","volume":"72","author":"Loomba","year":"2023","journal-title":"Gut"},{"issue":"1","key":"zoi241536r42","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"zoi241536r45","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.jceh.2022.12.005","article-title":"The growing economic and clinical burden of nonalcoholic steatohepatitis (NASH) in the United States.","volume":"13","author":"Younossi","year":"2023","journal-title":"J Clin Exp Hepatol"},{"issue":"1","key":"zoi241536r46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/apt.17734","article-title":"Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.","volume":"59","author":"Harrison","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"10213","key":"zoi241536r47","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"zoi241536r48","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial.","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"zoi241536r49","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH.","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi241536r50","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","article-title":"Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH.","volume":"389","author":"Loomba","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"zoi241536r51","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi241536r52","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi241536r53","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi241536r54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi241536r55","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","article-title":"A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.","volume":"78","author":"Ajmera","year":"2023","journal-title":"J Hepatol"},{"issue":"8","key":"zoi241536r56","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"zoi241536r58","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23952","article-title":"Early- and later-stage persistence with antiobesity medications: a retrospective cohort study.","author":"Gasoyan","journal-title":"Obesity (Silver Spring)"},{"issue":"2","key":"zoi241536r59","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3748\/wjg.v20.i2.475","article-title":"Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis.","volume":"20","author":"Sumida","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"5","key":"zoi241536r60","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1136\/gutjnl-2021-324243","article-title":"Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis.","volume":"71","author":"M\u00f3zes","year":"2022","journal-title":"Gut"},{"issue":"8","key":"zoi241536r61","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/S2468-1253(23)00141-3","article-title":"Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.","volume":"8","author":"M\u00f3zes","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"zoi241536r62","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/S2468-1253(23)00017-1","article-title":"Biomarkers for staging fibrosis and non-alcoholic steatohepatitis in non-alcoholic fatty liver disease (the LITMUS project): a comparative diagnostic accuracy study.","volume":"8","author":"Vali","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"zoi241536r63","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.jhep.2020.03.036","article-title":"Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: a systematic review and meta-analysis.","volume":"73","author":"Vali","year":"2020","journal-title":"J Hepatol"},{"issue":"4","key":"zoi241536r64","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review.","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"},{"key":"zoi241536r27","unstructured":"US Census Bureau. Census datasets. Accessed September 30, 2024. https:\/\/www.census.gov\/data\/datasets.html"},{"key":"zoi241536r36","unstructured":"Surveillance Epidemiology and End Results Program. Cancer stat facts: liver and intrahepatic bile duct cancer. Accessed March 20, 2023. https:\/\/seer.cancer.gov\/statfacts\/html\/livibd.html"},{"key":"zoi241536r37","unstructured":"Department of Health and Human Services, Health Resources and Services Administration, Organ Procurement and Transplantation Network. Transplant data 2008-2015. Accessed May 31, 2019. https:\/\/optn.transplant.hrsa.gov\/data\/view-data-reports\/national-data\/"},{"key":"zoi241536r38","unstructured":"National Center for Health Statistics, Centers for Disease Control and Prevention. Life tables. Accessed March 15, 2023. https:\/\/www.cdc.gov\/nchs\/products\/life_tables.htm"},{"key":"zoi241536r40","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. National Health and Nutrition Examination Survey, 2017-2018. Accessed Jan 30, 2023. https:\/\/www.cdc.gov\/nchs\/nhanes\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/nchs\/nhanes\/index.htm"},{"key":"zoi241536r43","unstructured":"Centers for Disease Control and Prevention. National Diabetes Statistics Report. Accessed March 7, 2024. https:\/\/www.cdc.gov\/diabetes\/php\/data-research\/index.html"},{"key":"zoi241536r44","unstructured":"Centers for Disease Control and Prevention. Nutrition, physical activity, and obesity data. Accessed March 07, 2024. https:\/\/www.cdc.gov\/nccdphp\/dnpao\/data-trends-maps\/index.html"},{"key":"zoi241536r57","unstructured":"Office of the Assistant Secretary for Planning and Evaluation. Price increases for prescription drugs, 2016-2022. Published September 30, 2022. Accessed December 9, 2024. https:\/\/aspe.hhs.gov\/reports\/prescription-drug-price-increases"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2829360\/le_2025_oi_241536_1736459207.0858.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T11:31:20Z","timestamp":1737113480000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2829360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.54707","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]}}}